BMO Capital Markets set a $1.00 price objective on Regulus Therapeutics (NASDAQ:RGLS) in a research report released on Thursday morning. The firm currently has a hold rating on the biopharmaceutical company’s stock.
Several other analysts have also weighed in on RGLS. Zacks Investment Research lowered Regulus Therapeutics from a buy rating to a hold rating in a report on Thursday, January 18th. Chardan Capital restated a neutral rating on shares of Regulus Therapeutics in a report on Tuesday, January 16th. Leerink Swann began coverage on Regulus Therapeutics in a report on Friday, January 5th. They issued an outperform rating and a $2.00 price objective for the company. Wedbush reaffirmed an outperform rating and set a $4.00 target price on shares of Regulus Therapeutics in a report on Monday, December 11th. Finally, Needham & Company LLC reaffirmed a hold rating on shares of Regulus Therapeutics in a report on Tuesday, November 14th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company. Regulus Therapeutics presently has a consensus rating of Hold and a consensus price target of $2.20.
Shares of Regulus Therapeutics (RGLS) opened at $0.95 on Thursday. The company has a quick ratio of 6.77, a current ratio of 6.77 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $98.55, a price-to-earnings ratio of -0.85 and a beta of 1.72. Regulus Therapeutics has a twelve month low of $0.79 and a twelve month high of $1.95.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. BVF Inc. IL raised its position in Regulus Therapeutics by 7.9% during the fourth quarter. BVF Inc. IL now owns 13,974,249 shares of the biopharmaceutical company’s stock valued at $14,533,000 after buying an additional 1,025,020 shares during the period. Renaissance Technologies LLC raised its position in Regulus Therapeutics by 215.7% during the fourth quarter. Renaissance Technologies LLC now owns 137,589 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 94,000 shares during the period. Ascend Capital LLC acquired a new position in Regulus Therapeutics during the fourth quarter valued at $1,053,000. Victory Capital Management Inc. raised its position in Regulus Therapeutics by 18.2% during the fourth quarter. Victory Capital Management Inc. now owns 327,770 shares of the biopharmaceutical company’s stock valued at $341,000 after buying an additional 50,530 shares during the period. Finally, GSA Capital Partners LLP raised its position in Regulus Therapeutics by 44.8% during the third quarter. GSA Capital Partners LLP now owns 203,815 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 63,100 shares during the period. 53.72% of the stock is owned by institutional investors and hedge funds.
About Regulus Therapeutics
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.